Xiao-Xuan Cai

Ms. Xiao-Xuan Cai

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Hua-Li ZuoHua-Li Zuo
Hua-Li Zuo
HHHsi-Yuan Huang
Hsi-Yuan Huang
YLYang-Chi-Dung Lin
Yang-Chi-Dung Lin
XCXiao-Xuan Cai
Xiao-Xuan Cai
XKXiang-Jun Kong
Xiang-Jun Kong
HHHsien-Da Huang
Hsien-Da Huang
Drug-metabolizing enzymes, particularly the cytochrome P450 (CYP450) monooxygenases, play a pivotal role in pharmacokinetics. CYP450 enzymes can be affected by various xenobiotic substrates, which will eventually be responsible for most metabolism-based herb–herb or herb–drug interactions, usually involving competition with another drug for the same enzyme binding site. Compounds from herbal or natural products are involved in many scenarios in the context of such interactions. These interactions are decisive both in drug discovery regarding the synergistic effects, and drug application regarding unwanted side effects. Herein, this review was conducted as a comprehensive compilation of the effects of herbal ingredients on CYP450 enzymes. Nearly 500 publications reporting botanicals’ effects on CYP450s were collected and analyzed. The countries focusing on this topic were summarized, the identified herbal ingredients affecting enzyme activity of CYP450s, as well as methods identifying the inhibitory/inducing effects were reviewed. Inhibitory effects of botanicals on CYP450 enzymes may contribute to synergistic effects, such as herbal formulae/prescriptions, or lead to therapeutic failure, or even increase concentrations of conventional medicines causing serious adverse events. Conducting this review may help in metabolism-based drug combination discovery, and in the evaluation of the safety profile of natural products used therapeutically.

20 February 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
LTLin Tingsyuan
Lin Tingsyuan
XCXiao-Xuan Cai
Xiao-Xuan Cai
YWYi-Bing Wang
Yi-Bing Wang
JXJia-Tong Xu
Jia-Tong Xu
JXJi-Han Xiao
Ji-Han Xiao
YLYang-Chi-Dung Lin
Yang-Chi-Dung Lin
Background: XueBiJing injection (XBJ) is renowned for its multi-target pharmacological effects, including immunomodulatory, antithrombotic, and antioxidant activities, offering potential therapeutic benefits for patients with severe infections such as sepsis and Coronavirus disease 2019 (COVID-19). Despite its clinical effectiveness, the molecular targets and mechanisms of XBJ remain unclear, warranting further investigation. Purpose: This study aimed to identify the key bioactive compounds in XBJ and elucidate their molecular targets and mechanisms. Methods: The zebrafish model was first used to evaluate the anti-inflammatory and antioxidant effects of XBJ, and the differentially expressed genes (DEGs) were identified by RNA sequencing and network analysis. Network pharmacology was used to analyze the relationship between bioactive compounds and molecular targets, and molecular docking and kinetic simulation were used to explore the target binding ability of key compounds. Cellular Thermal Shift Assay-Western Blot (CETSA-WB) and Surface Plasmon Resonance (SPR) further verified the interaction between compounds and targets; finally, the key pathways were confirmed by gene silencing experiments. Results: The zebrafish model results reveal that XBJ significantly reduced neutrophil and macrophage counts in a dose-dependent manner, emphasizing its potent anti-inflammatory effects. A transcriptomic analysis highlighted the differential expression of key genes in the KEAP1/NRF2 pathway, including HMOX1, SLC7A11, NQO1, and TXNRD1. A network analysis further pinpointed KEAP1 as a central molecular target, with tanshinone IIA, baicalein, and luteolin identified as key active compounds modulating this pathway. Among these, tanshinone IIA and baicalein exhibited strong binding interactions with KEAP1, which were confirmed through molecular docking and kinetic simulations. Further validation showed that baicalein directly targets KEAP1, as demonstrated by CETSA-WB and SPR analysis. Additionally, the gene silencing experiments of KEAP1 and NRF2 reinforced their crucial roles in activating the KEAP1/NRF2 pathway. Conclusion: These findings collectively establish baicalein as a critical bioactive compound in XBJ, driving its antioxidant and anti-inflammatory effects via KEAP1/NRF2 pathway activation through direct binding to KEAP1, providing new insights into the mechanism of action of XBJ.

15 February 2026 in Advanced Science
Verified
Journal Article
Open access
XCXiao-Xuan Cai
Xiao-Xuan Cai
JLJing‐Shan Liao
Jing‐Shan Liao
JMJia‐Jun Ma
Jia‐Jun Ma
YPYu‐Xuan Pang
Yu‐Xuan Pang
YCYi‐Gang Chen
Yi‐Gang Chen
HHHsien-Da Huang
Hsien-Da Huang
MicroRNAs (miRNAs) are pivotal post‑transcriptional regulators whose single‑cell behavior has remained largely inaccessible due to technical barriers in single‐cell small‑RNA profiling. We present SiCmiR, a two‑layer neural network that predicts miRNA expression profiles from only 977 LINCS L1000 landmark genes, thereby reducing sensitivity to dropout in single‐cell RNA‐seq (scRNA‐seq) data. Proof‑of‑concept analyses illustrate how SiCmiR can uncover candidate hub‑miRNAs in bulk‐seq cell lines and hepatocellular carcinoma, scRNA‐seq pancreatic ductal carcinoma, and ACTH‑secreting pituitary adenoma and extracellular vesicle (EV)‑mediated crosstalk in glioblastoma. Trained on 6,462 TCGA paired miRNA–mRNA samples, SiCmiR attains state‑of‑the‑art accuracy on cancers and generalizes to unseen cancer types and drug perturbations. We next construct SiCmiR‑Atlas, containing 362 public datasets, 9.36 million cells, and 726 cell types, which is the first dedicated database of single‑cell mature miRNA expression, providing interactive visualization, biomarker identification, and cell‑type‑resolved miRNA–target networks. SiCmiR transforms bulk‑derived statistical power into a single‑cell view of miRNA biology and provides a community resource for biomarker discovery. SiCmiR Atlas is available at https://awi.cuhk.edu.cn/∼SiCmiR/.

15 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
XCXiao-Xuan Cai
Xiao-Xuan Cai
Hua-Li ZuoHua-Li Zuo
Hua-Li Zuo
JLJing Li
Jing Li
HHHsi-Yuan Huang
Hsi-Yuan Huang
LLLi-Ping Li
Li-Ping Li
YLYang-Chi-Dung Lin
Yang-Chi-Dung Lin
Background/Objectives: Glioblastoma (GBM), the most aggressive primary malignant brain tumor, has a dismal prognosis and limited treatment options. The dried rhizome of Ligusticum chuanxiong Hort. (Chuanxiong, CX) is a traditional Chinese medicinal herb frequently prescribed in formulas intended to invigorate blood circulation. CX also exhibits anti-glioma activity, but its molecular mechanisms remain incompletely understood. Methods: In this study, we combined transcriptomics and Raman spectroscopy to investigate the effects of reconstituted CX-dispensing granules (hereafter referred to as CXG solution) on U87MG cells, suggesting their dual role in promoting cell death and modulating collagen deposition and lipid metabolism. Results: Mechanistically, we demonstrated that the CXG solution downregulates hsa-miR-10a-5p, which directly targets BCL2L11, known to induce pro-apoptotic effects, as validated by qPCR and dual-luciferase reporter assays. Furthermore, the CXG solution and hsa-miR-10a-5p suppress lipid metabolism through a coherent feed-forward loop via targeting transcription factors SREBF1 and E2F1. An electrophoretic mobility shift assay (EMSA) confirmed E2F1 binds to the hsa-miR-29a promoter, leading to the synergistic repression of hsa-miR-29a-3p by SREBF1 and E2F1. Network pharmacology analysis combined with molecular docking suggested that the ferulic acid and adenosine in CX potentially modulate EGFR-the E2F1-hsa-miR-10a-5p axis. Conclusions: These findings elucidate CX’s multi-target anti-GBM mechanisms and propose a novel therapeutic strategy combining metabolic intervention with miRNA-targeted therapy, providing novel insights into feed-forward loop regulation in miRNA networks.

Verified
Journal Article
Open access
PDF file
JXJiatong Xu
Jiatong Xu
XCXiao-Xuan Cai
Xiao-Xuan Cai
JHJunyang Huang
Junyang Huang
HHHsi-Yuan Huang
Hsi-Yuan Huang
YWYong-Fei Wang
Yong-Fei Wang
HHHsien-Da Huang
Hsien-Da Huang
Triple-negative breast cancer (TNBC) poses a major clinical challenge due to its aggressive progression and limited treatment options, making early diagnosis and prognosis critical. MicroRNAs (miRNAs) are crucial post-transcriptional regulators that influence gene expression. In this study, we unveil novel miRNA–mRNA interactions and introduce a prognostic model based on miRNA–target interaction (MTI), integrating miRNA–mRNA regulatory correlation inference and the machine learning method to effectively predict the survival outcomes in TNBC cohorts. Using this method, we identified four key miRNAs (miR-181b-5p, miR-21-5p, miR-210-3p, miR-183-5p) targeting eight downstream target genes, forming a novel regulatory network of 19 validated miRNA–mRNA pairs. A prognostic model constructed based on the top 10 significant MTI pairs using random forest combination effectively classified patient survival outcomes in both TCGA and independent dataset GSE19783 cohorts, demonstrating good predictive accuracy and valuable prognostic insights for TNBC patients. Further analysis uncovered a complex network of 71 coherent feed-forward loops involving transcription factors, miRNAs, and target genes, shedding light on the mechanisms driving TNBC progression. This study underscores the importance of considering regulatory networks in cancer prognosis and provides a foundation for new therapeutic strategies aimed at improving TNBC treatment outcomes.

23 December 2025 in bioRxiv
Verified
Preprint
Open access
YLYang-Chi-Dung Lin
Yang-Chi-Dung Lin
YCYigang Chen
Yigang Chen
LTLin Tingsyuan
Lin Tingsyuan
XCXiao-Xuan Cai
Xiao-Xuan Cai
SHShenghan Huang
Shenghan Huang
HHHsien-Da Huang
Hsien-Da Huang
In response to environmental changes, bacteria have evolved sophisticated regulatory networks that incorporate small RNAs (sRNAs) and transcription factors (TFs) to fine-tune cellular physiology. Both sRNAs and TFs modulate gene expression, but the former function via post-transcriptional mechanisms, while the latter act at the transcriptional level. However, it remains unclear why both regulatory layers are conserved through evolution, rather than one being sufficient. Here, we experimentally identified that CRP, a global regulator, regulates 25 small RNAs (sRNAs) in Escherichia coli. Interestingly, CRP also controls 80% of the target genes of these sRNAs. This architecture led us to identify 34 novel sRNA-mediated feed-forward loops (sFFLs) circuits where CRP regulates both an sRNA and its target within the CRP regulon. Quantitative PCR analysis of 16 such sFFLs revealed that each type possesses a distinct cAMP dose-response profile, suggesting that different sFFL structures embody unique regulatory logic. Specifically, coherent and incoherent type 3 and 4 sFFLs exhibit broader dynamic ranges in their dose-response compared to open-loop controls. Coherent and incoherent type 1 and 2 sFFLs appear more energy-efficient. Altogether, we propose that sRNAs cooperate with TFs through sFFLs to optimize both the energy efficiency and the diversity of signal response profiles. Therefore, sRNAs serve as critical components integrating transcriptional and post-transcriptional networks across diverse cellular pathways.